Clinical trial
Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study
NCT00446862 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Multi-center, Open-label Study of the Safety and Efficacy of Control of Proteinuria With ACE Inhibitors and ARBS in Patients With Fabry Disease Who Are Receiving Fabrazyme®: The FAACET Study
- Lead sponsor
- University of Alabama at Birmingham
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- December 31, 2012
- Enrollment
- 36 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.